Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.06 Billion KRW | -147.54% |
| 2022 | -22.22 Billion KRW | 2047.8% |
| 2021 | 1.27 Billion KRW | -84.59% |
| 2020 | 21.04 Billion KRW | 13.59% |
| 2019 | 22.86 Billion KRW | -5.95% |
| 2018 | 19.11 Billion KRW | 21.03% |
| 2017 | 17.99 Billion KRW | 99.9% |
| 2016 | 10.32 Billion KRW | -51.16% |
| 2015 | 19.48 Billion KRW | -44.91% |
| 2014 | 32.31 Billion KRW | -12.67% |
| 2013 | 36.39 Billion KRW | 15.0% |
| 2012 | 32.05 Billion KRW | -29.14% |
| 2011 | 46.01 Billion KRW | -8.95% |
| 2010 | 52.28 Billion KRW | 19.17% |
| 2009 | 44.06 Billion KRW | 26.05% |
| 2008 | 32.33 Billion KRW | 34.94% |
| 2007 | 25.7 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 1 Billion KRW | 150.76% |
| 2024 Q1 | -645.41 Million KRW | 106.84% |
| 2023 Q1 | 19.14 Billion KRW | -80.71% |
| 2023 Q2 | 21.9 Billion KRW | 14.37% |
| 2023 Q4 | -12.73 Billion KRW | -164.97% |
| 2023 Q3 | 19.6 Billion KRW | -10.48% |
| 2023 FY | - KRW | -147.54% |
| 2022 Q2 | 446.04 Million KRW | 113.39% |
| 2022 Q4 | 99.24 Billion KRW | 1189.17% |
| 2022 FY | - KRW | 2047.8% |
| 2022 Q3 | -9.11 Billion KRW | -2142.8% |
| 2022 Q1 | -3.33 Billion KRW | 34.99% |
| 2021 Q1 | 5.68 Billion KRW | -7.81% |
| 2021 Q2 | 2.88 Billion KRW | -49.21% |
| 2021 Q3 | 186.71 Million KRW | -93.53% |
| 2021 Q4 | -5.12 Billion KRW | -2845.1% |
| 2021 FY | - KRW | -84.59% |
| 2020 Q4 | 6.16 Billion KRW | 22.35% |
| 2020 Q1 | 7 Billion KRW | 629.14% |
| 2020 FY | - KRW | 13.59% |
| 2020 Q3 | 5.03 Billion KRW | -5.88% |
| 2020 Q2 | 5.35 Billion KRW | -23.55% |
| 2019 Q3 | 7.44 Billion KRW | 10.46% |
| 2019 Q2 | 6.74 Billion KRW | 20.66% |
| 2019 Q1 | 5.58 Billion KRW | 23.92% |
| 2019 Q4 | 960.21 Million KRW | -87.11% |
| 2019 FY | - KRW | -5.95% |
| 2018 Q4 | 4.5 Billion KRW | -22.1% |
| 2018 FY | - KRW | 21.03% |
| 2018 Q3 | 5.78 Billion KRW | -15.28% |
| 2018 Q2 | 6.83 Billion KRW | 38.95% |
| 2018 Q1 | 4.91 Billion KRW | 377.89% |
| 2017 Q2 | 7.85 Billion KRW | 48.52% |
| 2017 Q1 | 5.28 Billion KRW | 266.62% |
| 2017 FY | - KRW | 99.9% |
| 2017 Q4 | -1.76 Billion KRW | -125.74% |
| 2017 Q3 | 6.87 Billion KRW | -12.46% |
| 2016 Q3 | 4.53 Billion KRW | 27.37% |
| 2016 Q4 | -3.17 Billion KRW | -169.93% |
| 2016 Q1 | 4.41 Billion KRW | -50.83% |
| 2016 FY | - KRW | -51.16% |
| 2016 Q2 | 3.56 Billion KRW | -19.22% |
| 2015 FY | - KRW | -44.91% |
| 2015 Q1 | 5.14 Billion KRW | -11.96% |
| 2015 Q4 | 8.97 Billion KRW | 1137.57% |
| 2015 Q3 | 724.95 Million KRW | -66.96% |
| 2015 Q2 | 2.19 Billion KRW | -57.32% |
| 2014 Q4 | 5.83 Billion KRW | -44.24% |
| 2014 Q1 | 7.08 Billion KRW | 20.68% |
| 2014 FY | - KRW | -12.67% |
| 2014 Q2 | 8.99 Billion KRW | 26.89% |
| 2014 Q3 | 10.47 Billion KRW | 16.45% |
| 2013 Q2 | 10.13 Billion KRW | -4.43% |
| 2013 Q3 | 6.71 Billion KRW | -33.77% |
| 2013 Q4 | 5.87 Billion KRW | -12.54% |
| 2013 FY | - KRW | 15.0% |
| 2013 Q1 | 10.6 Billion KRW | 80.32% |
| 2012 Q4 | 5.88 Billion KRW | -38.87% |
| 2012 FY | - KRW | -29.14% |
| 2012 Q1 | 6.19 Billion KRW | 0.0% |
| 2012 Q2 | 5.67 Billion KRW | -8.3% |
| 2012 Q3 | 9.62 Billion KRW | 69.42% |
| 2011 Q2 | 11.92 Billion KRW | -19.38% |
| 2011 Q3 | 6.94 Billion KRW | -41.79% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | -8.95% |
| 2011 Q1 | 14.79 Billion KRW | 0.0% |
| 2010 Q1 | 13.76 Billion KRW | 0.0% |
| 2010 FY | - KRW | 19.17% |
| 2010 Q3 | 9.56 Billion KRW | -27.7% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 13.22 Billion KRW | -3.94% |
| 2009 Q1 | 6.38 Billion KRW | 0.0% |
| 2009 Q2 | 10.84 Billion KRW | 69.75% |
| 2009 Q3 | 13.05 Billion KRW | 20.45% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | - KRW | 26.05% |
| 2008 Q3 | 6.94 Billion KRW | -30.79% |
| 2008 Q1 | 8.21 Billion KRW | 0.0% |
| 2008 FY | - KRW | 34.94% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 10.03 Billion KRW | 22.23% |
| 2007 Q3 | 4.69 Billion KRW | -46.49% |
| 2007 Q2 | 8.76 Billion KRW | 73.63% |
| 2007 Q1 | 5.04 Billion KRW | 0.0% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 862.953% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 126.221% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 42.116% |
| HANDOK Inc. | 35.06 Billion KRW | 205.704% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -3475.895% |
| Yuhan Corporation | 127.43 Billion KRW | 129.087% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 198.789% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | -70.913% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 111.464% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 842.774% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 345.18% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 1183.517% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 918.903% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 204.454% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 862.953% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | -100.667% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 665.477% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 24.801% |
| JW Holdings Corporation | 187.88 Billion KRW | 119.728% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 27.644% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 113.069% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 141.545% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 380.605% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 413.386% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 298.698% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 862.953% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 167.427% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 122.477% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 141.545% |
| Yuhan Corporation | 127.43 Billion KRW | 129.087% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 210.727% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 584.545% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 148.121% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 141.545% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 201.18% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 152.369% |
| CKD Bio Corp. | -1.63 Billion KRW | -2173.421% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 174.442% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 213.836% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 200.697% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | -0.0% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 159.512% |
| Boryung Corporation | 114.28 Billion KRW | 132.433% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | -21.259% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 345.18% |
| JW Lifescience Corporation | 50.82 Billion KRW | 172.924% |